Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Written informed consent must be obtained before any assessment is performed.
Recipients of a kidney transplant from a heart-beating deceased, living unrelated or non-human leukocyte antigen (HLA) identical living related donor.
Recipients of a kidney with a cold ischemia time (CIT) \< 30 hours.
You may not be if
Recipients of an organ from a non-heart beating donor.
ABO incompatible or complement-dependent lymphocytotoxic (CDC) crossmatch positive transplant.
Subjects receiving a second kidney allograft, unless the first allograft was lost due to surgical complication.
Subjects at high immunological risk for rejection
Subjects at risk for tuberculosis (TB)
Subject with severe systemic infections, current or within the two weeks prior to randomization/enrollment.
Any additional contraindication to the use of tacrolimus or mycophenolate mofetil according to the national labeling information of these products (see local product label).
Clareo Health | CCFZ533X2201 - PoC Study in de Novo Renal Transplantation
